ESMO 2026: IDYA / ORIC / ZLAB - Quick Takes on Select Abstracts

This report provides quick takes on selected ESMO 2026 abstracts for IDEAYA Biosciences (IDYA), ORIC Pharmaceuticals (ORIC) and Zai Lab (ZLAB), all rated Overweight. The update focuses on darovasertib. In OptimUM-01, 101 HLA-A*02:01-positive patients with metastatic uveal melanoma received darovasertib plus crizotinib; in the first-line subgroup, median OS was 27.1 months, median PFS 7.4 months and median DOR 10.2 months, with an ORR of 36.4% and a DCR of 90.9%, versus historical median PFS of 2.8 months and median OS of 12 months. OptimUM-02 showed consistent ORR/PFS benefit versus ICT across clinically relevant subgroups in first-line HLA-A2-negative patients. In the phase 2 OptimUM-09 neoadjuvant study (n=116), 57.1% of C1 patients became eligible for eye preservation, 66% of C2 patients had their planned radiation dose reduced, about 80% had tumor shrinkage, and the 15-month metastasis-free rate was about 86%, with manageable safety. The data continue to support darovasertib's emer